| |
|
|
|
Aldeyra Therapeutics Inc.  
|
|
9.9 -0.1 (0.03%) |
09-25 16:00 |
|
Open: |
10 |
Pre close: |
9.65 |
Target:
|
12.38
|
|
High: |
10.1 |
Low: |
8.75 |
Resistance:
|
10.60
12.38
|
|
Volume: |
264,178 |
Market Cap: |
208M |
Support:
|
8.41
7.05
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
9.04
 |
MACD |
MACD(12,26):
|
0.40 |
|
MA(20): |
8.23 |
Signal(12,26,9): |
0.21 |
|
MA(100): |
8.06 |
Stochastic Oscillator |
%K(14,3):
|
73.97  |
|
MA(250): |
7.49 |
%D(3): |
72.36 |
|
Average Volume(K) |
3-Month: |
9688
|
52-Week |
High:
|
10.60 |
|
10-Days: |
19002 |
Low: |
5.55 |
|
RSI |
RSI(14):
|
76.04 |
Change(%): |
35.6 |
|
Financials, Statistics and Valuation |
|
EPS |
-1.580 |
Return on Equity (ttm) |
-96.6 |
Shares Out. (M) |
20.97 |
|
EPS Est. Current Year |
-1.470 |
Return on Assets (ttm) |
-83.5 |
Shares Float (M) |
20.55 |
|
EPS Est. Next Year |
-1.740 |
PEG Ratio |
0.00 |
% Held by Insiders |
0.00 |
|
EPS Est. Next Quarter |
-0.370 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
47.20 |
|
Forward EPS |
-2.372 |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
369 |
|
Book Value (p.s.) |
4.820 |
EBITDA (p.s.) |
-0.236 |
P/E |
-6.27 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
2.05 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-23.92 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
-30.40 |
P/CF |
-8.68 |
|
|
|
|
|
|
